This report provides comprehensive
information on the therapeutic development for Systemic Sclerosis
(Scleroderma), complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and
featured news and press releases. It also reviews key players involved in the
therapeutic development for Systemic Sclerosis (Scleroderma) and special
features on late-stage and discontinued projects.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/systemic-sclerosis-scleroderma-pipeline-review-h1-2014
Global Markets Directs report
features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and
information sourced from Global Markets Directs proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Directs team. Drug profiles/records
featured in the report undergoes periodic updation following a stringent set
of processes that ensures that all the profiles are updated with the latest
set of information. Additionally, processes including live news & deals
tracking, browser based alert-box and clinical trials registries tracking
ensure that the most recent developments are captured on a real time basis.
The report enhances decision making
capabilities and help to create effective counter strategies to gain
competitive advantage. It strengthens R&D pipelines by identifying new
targets and MOAs to produce first-in-class and best-in-class products.
Scope
- The report provides a snapshot
of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
- The report reviews key
pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details &
other developmental activities
- The report reviews key players
involved in the therapeutics development for Systemic Sclerosis
(Scleroderma) and enlists all their major and minor projects
- The report summarizes all the
dormant and discontinued pipeline projects
- A review of the Systemic
Sclerosis (Scleroderma) products under development by companies and
universities/research institutes based on information derived from
company and industry-specific sources
- Pipeline products coverage
based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- A detailed assessment of
monotherapy and combination therapy pipeline projects
- Coverage of the Systemic
Sclerosis (Scleroderma) pipeline on the basis of target, MoA, route of
administration and molecule type
- Latest news and deals relating
related to pipeline products
Reasons to buy
- Provides strategically
significant competitor information, analysis, and insights to formulate
effective R&D development strategies
- Identify emerging players with
potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage
- Develop strategic initiatives
by understanding the focus areas of leading companies
- Identify and understand
important and diverse types of therapeutics under development for
Systemic Sclerosis (Scleroderma)
- Plan mergers and acquisitions
effectively by identifying key players of the most promising pipeline
- Devise corrective measures for
pipeline projects by understanding Systemic Sclerosis (Scleroderma)
pipeline depth and focus of Indication therapeutics
- Develop and design
in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand business
potential and scope
- Modify the therapeutic
portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline
Contact US: 
|
Office: United States
|
|
State Tower
90 State Street, Suite 700 Albany, NY 12207 United States |
No comments:
Post a Comment